3 hours Black Diamond Therapeutics (NASDAQ:BDTX) Given “Outperform” Rating at Wedbush MarketBeat
Wedbush reiterated an “outperform” rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research report on Tuesday.
Wedbush reiterated an “outperform” rating and issued a $16.00 price objective on shares of Black Diamond Therapeutics in a research report on Tuesday.